Discovery of Pyrimidoindolones as Novel Family VIII Bromodomain Binders

Suppression of oncogenic gene expression is an effective strategy for the treatment of cancer. The SWI/SNF (SWItch/Sucrose Non-Fermentable) complex plays an important role in regulating gene activation or repression, and its dysregulation has been linked to aberrant transcription activity in many types of cancer. Targeting the subunits of this complex, such as SMARCA2, SMARCA4, and PBRM1, which are part of the bromodomain family VIII, has significant therapeutic potential. Herein we report the discovery of pyrimidoindolones as a novel series of bromodomain family VIII binders identified through an NMR-based fragment screen. These binders have been optimized to achieve sub-μM affinity for the family VIII proteins SMARCA2, SMARCA4, and PRBM1, with promising physicochemical properties.

Authors

Institutions

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2025-05-08
DOI
https://doi.org/10.1021/acsmedchemlett.5c00120
Citations
1
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of Pyrimidoindolones as Novel Family VIII Bromodomain Binders

Paolo Di Fruscia, Marianne Schimpl, Alexander G. Milbradt, Kevin J. Embrey et al.
1 citations
ACS Medicinal Chemistry Letters
Protein Degradation and Inhibitors
0.81
article

Discovery of Pyrimidoindolones as Novel Family VIII Bromodomain Binders

Paolo Di Fruscia, Marianne Schimpl, Alexander G. Milbradt, Kevin J. Embrey, Ariamala Gopalsamy, Richard Storer, Philip B. Rawlins, Jennifer E. Nelson, Victoria Korboukh, Erin Code, Jeffrey A. Boerth, Andrea Gohlke, Ulf Börjesson, Haixia Wang, Simon C. C. Lucas, Jingwen Zhang
article en
1 citations

Abstract

Suppression of oncogenic gene expression is an effective strategy for the treatment of cancer. The SWI/SNF (SWItch/Sucrose Non-Fermentable) complex plays an important role in regulating gene activation or repression, and its dysregulation has been linked to aberrant transcription activity in many types of cancer. Targeting the subunits of this complex, such as SMARCA2, SMARCA4, and PBRM1, which are part of the bromodomain family VIII, has significant therapeutic potential. Herein we report the discovery of pyrimidoindolones as a novel series of bromodomain family VIII binders identified through an NMR-based fragment screen. These binders have been optimized to achieve sub-μM affinity for the family VIII proteins SMARCA2, SMARCA4, and PRBM1, with promising physicochemical properties.

ACS Medicinal Chemistry LettersVol. 16(6)
Bioscience Research (US), AstraZeneca (Brazil) (BR), Medicina (PL)
Zero hunger
Openalex Percentile: Top 28%
Protein Degradation and Inhibitors
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.